US healthcare company Baxter has begun enrolment for its Phase III clinical trial of a drug that is a combination of citrate anticoagulant and renal replacement solution to treat acute kidney-injury patients receiving continuous renal replacement therapy (CRRT).

The Phase III multi-centre, prospective, randomised, controlled clinical trial will examine the efficacy of the citrate coagulant with renal replacement solution on the extracorporeal circuit life in 160 patients admitted in intensive care unit (ICU) treated with CRRT.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The trial will be conducted through the course of next year.

The patients will be randomised to receive either CRRT with regional citrate anticoagulant (Prismocitrate 18) or CRRT with no anti-coagulant.

"One potential obstacle in delivering effective CRRT occurs when blood flow through the circuit is slowed or completely stopped by blood clots."

Baxter acute therapies medical director Farah Ali said: ''One potential obstacle in delivering effective CRRT occurs when blood flow through the circuit is slowed or completely stopped by blood clots.

''Extending the life of the extracorporeal circuit can help patients with acute kidney injury remain on renal replacement therapy as prescribed, while reducing potential complications that can occur when the blood circuit needs to be replaced.''

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

During CRRT, blood passes through the extracorporeal circuit to help clear waste products in the blood, returning it to a normal state. This cleaned blood is then returned to the body.

Clinicians can prescribe an anticoagulant to help reduce the likelihood of circuit clotting. When blood flow through the circuit is interrupted, patients may not receive the prescribed dose of CRRT, which may impact its effectiveness.

If approved, the product will offer a standardised formulation of renal replacement fluid combined with a citrate anticoagulant.

Combining two different drug solutions together may make it easier for healthcare providers to administer therapy at the bedside.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact